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TO THE EDITOR
Chronic actinic dermatitis (CAD) is an
uncommon photosensitivity disease,
characterized by a photoexposed site
dermatitis that may be severe and
disabling (Kerr and Ibbotson, 2006)
(Supplementary Figure S1 online). Objec-
tive evidence of broadband photosensi-
tivity to UVB and often also UVA and
visible wavebands is evident and most
patients also have multiple contact
allergies (Frain-Bell et al., 1974). The
condition occurs worldwide, although it
is more common in temperate climates
and typically develops in middle-aged
to elderly males. Most individuals have
a history of a preceding dermatitis,
either atopic, contact allergic, or sebor-
rhoeic, although it can occur de novo
(Frain-Bell et al, 1974; Hawk, 2004;
Kerr and Ibbotson, 2006). Resolution of
photosensitivity is reported in up to
50% of individuals after 15 years or
more, with contact allergies persisting
(Dawe et al., 2000).
The pathogenesis of CAD is incom-
pletely understood; cases are sporadic
and genetic risk factors have not been
identiﬁed. Histology and immunohisto-
chemistry of UVR-induced lesional skin
are consistent with an immunological
delayed-type hypersensitivity reaction
(Menage et al., 1996). Given the asso-
ciations with contact allergies and
atopic eczema, we considered that
epidermal barrier dysfunction might be
a key factor in pathogenesis. The
characteristic photosensitivity indicates
aberrant cutaneous responses to UVR
are also likely to be implicated. Filaggrin
is an important structural protein in the
epidermis (Smith et al., 2006). Loss-of-
function mutations in the gene
encoding ﬁlaggrin (FLG) are associated
with skin barrier dysfunction and
increased risk of atopic eczema
(Palmer et al., 2006; Baurecht et al.,
2007). Filaggrin is degraded to release
amino acids in the stratum corneum and
FLG mutations lead to reduction in
photo-absorbing amino acids, speciﬁ-
cally urocanic acid (UCA), a chromo-
phore for UVB that may protect against
photodamage (de Fine Olivarius et al.,
1996; Mildner et al., 2010; Barresi
et al., 2011). We aimed to test the
hypothesis that FLG loss-of-function
mutations are associated with increased
risk of CAD, supporting a role for lack of
intrinsic photoprotection and/or skin
barrier dysfunction in the pathogenesis
of CAD.
This study was conducted in accor-
dance with the Declaration of Helsinki
Principles; written informed consent
was obtained from all participants.
Sequential patients aged ≥ 18 years
attending the National Photodiagnostic
Service and diagnosed with CAD were
invited to participate. The diagnosis was
based on clinical and photobiological
assessment (including monochromator
phototesting) by a photodermatologist.
Patient-reported history of atopic dis-
ease was recorded. Patch testing was
performed as clinically indicated. Blood
was taken for total IgE levels and DNA
analysis. DNA samples were analyzed
for FLG mutations within the CAD cases
of white European ethnicity and in 100
Scottish population-matched controls.
The four most prevalent FLG loss-of-
function mutations in this population
were screened (R501X, 2282del4,
R2247X, and S3247X) as previously
described (Kezic et al., 2011). The χ2
and logistic regression analyses were
used to test for association between
CAD and FLG combined null genotype
in Stata (version 13; StataCorp LP,
College Station, TX).
A total of 55 patients were recruited;
the clinical characteristics and investi-
gation ﬁndings are summarized in
Table 1. The mean age of onset of
photosensitivity was 50.2 (range 21–77)
years. The majority (35/55, 63.6%) had
marked UVB sensitivity (o50% of
lower limit of normal) and 25 patients
(45.5%) had abnormal photosensitivity
to UVB, UVA, and visible wavebands
(Table 1). Photosensitivity had resolved
by the time of recruitment in three cases
(5.5%). Most patients (42/55; 76.4%) had
positive patch testing, including 37
(88.1%) with multiple allergen reactions.
Of those with contact allergy, the median
number of allergens was 4 (range 2–31).
A diagnosis of atopic disease (eczema,
asthma, allergic rhinitis, or type I hyper-
sensitivity reaction) was noted in 23
(41.8%) patients. Total IgE levels were
elevated in the majority (Table 1).
Genotyping results were obtained for
all four of the FLG mutations in 48/49
cases (Table 2 and Supplementary
Figure S2 online), of whom 10 had a
FLG mutation (20.4%). Of these 49
patients, 22 (44.9%) demonstrated ato-
pic comorbidity and of the cases carry-
ing a FLG mutation, 6/10 had a history
of atopic eczema; in one patient the
atopic status was not recorded. In the
control group, 12/100 (12.0%) indivi-
duals were heterozygous for a FLG
loss-of-function mutation but this was
not signiﬁcantly different from the pre-
valence seen in the cases (χ2 P= 0.16,
odds ratio (OR)= 1.92, 95% conﬁdence
interval (CI)= 0.77–4.85). The appar-
ently higher prevalence of FLG muta-
tions within the cases compared with
controls may reﬂect the co-association
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of atopic eczema with CAD, and sub-
group analysis of the small number of
atopic CAD cases (n= 22) showed a
borderline but nonsigniﬁcant associa-
tion with FLG-null genotype (P= 0.05,
OR= 2.93, 95% CI= 0.95–9.01). In
contrast, the nonatopic cases (n= 26)
showed no association with FLG geno-
type (P= 0.95, OR= 0.96, 95% CI=
0.25–3.67).
To assess whether the lack of associa-
tion of FLG-null mutations with CAD is
a true negative result or a reﬂection of
the lack of statistical power, we per-
formed a power calculation using
Quanto 1.2 (http://biostats.usc.edu/soft
ware). The CAD prevalence is 1:2,000
within the Tayside area of Scotland
(Dawe, 2005), and FLG-null allele
frequency is 0.06 (Table 2), and there-
fore 48 cases and 100 controls provide
475% power to detect an OR of ≥ 3.2.
CAD generally occurs on the back-
ground of preexisting dermatitis, but the
mechanisms triggering photosensitivity
remain unclear. The chromophore(s)
and the nature of UV-induced neoanti-
gen initiation of a delayed hypersensi-
tivity reaction remain unknown (Hawk,
2004). Proﬁlaggrin and ﬁlaggrin are
multifunctional proteins contributing to
epidermal barrier formation and func-
tion (Brown and McLean, 2012), limit-
ing allergen penetration and facilitating
photoprotection. There is growing
evidence that FLG mutations are strongly
associated with delayed-type hypersen-
sitivity (Thyssen et al., 2013), and
therefore FLG represents a candidate
gene in CAD. The lack of association
in this study has effectively excluded
FLG-null genotype as playing a
strong role (OR 43.2) in CAD patho-
genesis, and further research is needed
to deﬁne key pathomechanisms. Our
data represent one of the largest
collections of carefully phenotyped
cases of this uncommon but highly
symptomatic photodermatosis. Despite
increasing clinical understanding of
CAD, knowledge of mechanisms and
thus of informed treatment options
remains limited and further studies are
indicated.
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Table 1. Demographic, clinical, and investigative characteristics of CAD
cases and population controls
Characteristic N (%)
Cases Total 55
Male 28 (50.9)
Female 27 (49.1)
Fitzpatrick skin type I–III (including 10 FLG heterogygotes)1 49 (89.1)
Fitzpatrick skin type IV–VI (FLG genotype undeﬁned) 6 (10.9)
Abnormal photosensitivity by waveband (at time of recruitment) 55 cases
UVB only (305± 5 nm) 0
UVA only (335/365±30 nm) 1 (1.8)
Visible only (400±30 nm) 0
UVA and UVB 22 (40.0)
UVA and visible 4 (7.2)
All wavebands (UVB, UVA, and visible light) 25 (45.5)
Photosensitivity resolved 3 (5.5)
Degree of UVB (305±5 nm) sensitivity2
o10% Of normal 17 (30.9)
11–19% Of normal 7 (12.7)
20–49% 11 (20.0)
50–75% 11 (20.0)
≥76% 9 (16.4)
Atopic disease
Eczema, asthma, hay fever, or food allergy 23 (41.8)
Immunoglobulin E levels (Ku l−1)
Normal (o100) 13 (23.6)
100–999 17 (30.9)
1,000–5,000 10 (18.2)
45,000 6 (10.9)
Unavailable 9 (16.4)
Positive reactions to contact allergens 42/55 cases (76.4%)
Single 5 (11.9)
Multiple 37 (88.1)
Number of patch test series with positive reaction per patient
Single series 19 (45.2)
Two series 15 (35.7)
Three series 7 (16.7)
Four series 1 (2.4)
Commonest positive patch test series
BCD standard 38 (90.5)
Plants 12 (28.6)
Sunscreens3 7 (16.7)
Corticosteroids 3 (7.1)
Medicaments 3 (7.1)
Controls Total 100
Male 50 (50.0)
Female 50 (50.0)
Abbreviations: BCD, british contact dermatitis; CAD, chronic actinic dermatitis; FLG, ﬁlaggrin.
1Details provided in Table 2.
2Abnormal UVB sensitivity (assessed by monochromator phototesting at 305±5 nm (half-maximum
bandwidth)): the minimal erythemal dose (MED) expressed as a percentage of the lowest normal
value for MED at this waveband in healthy volunteers of skin phototypes I–III. The lower the MED, the
higher the level of abnormal photosensitivity. Thus, an MED of o10% of normal is the most
abnormally photosensitive.
3Sunscreen patch testing does not represent photopatch testing.
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TO THE EDITOR
Fibronectins (FNs) are high molecular
weight glycoproteins present in
extracellular connective tissue matrices
(ECM) and extracellular ﬂuids, includ-
ing blood plasma. The human FN gene
consists of 45 exons, and the pri-
mary mRNA transcripts are alternatively
spliced to form up to 20 different mRNA
variants (White et al., 2008). The
FNs interact with other matrix
macromolecules, such as collagens,
glycosaminoglycans, and ﬁbrin, as well
as cell surface receptors, including
Table 2. FLG genotyping results for patients of white European ethnicity
Cases, n (%) Controls, n (%)
Comorbid atopic disease 22 (44.9) Undetermined
FLG wild-type genotype 38 (77.6) 88 (88.0)
FLG heterozygote genotype 10 (20.4) 12 (12.0)
FLG homozygote or compound heterozygote 0 0
Incomplete genotyping data 1 (2.0) 0
Total 49 (100.0) 100 (100.0)
χ2 analysis P=0.16
Odds ratio (95% CI) 1.92 (0.77–4.85)
Abbreviations: CI, conﬁdence interval; FLG, ﬁlaggrin.
Cases with Fitzpatrick skin type of IV–VI were excluded from the genetic analysis because FLG loss-of-
function mutations remain ill deﬁned in these ethnic groups.
See related commentary on pg 1714
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